Skip to main content
. Author manuscript; available in PMC: 2022 Jan 5.
Published in final edited form as: Cancer Res. 2020 Nov 6;81(2):332–343. doi: 10.1158/0008-5472.CAN-19-3922

Figure 5. NVP-AUY922 inhibits tumor growth in ARID1A-deleted subcutaneous xenograft models.

Figure 5.

A-C. Tumor burden of mice engrafted with ARID1A-knock-out or parental cells, treated with NVP-AUY922 (75 mg/kg) or vehicle every day for 15 days after tumor establishment, via intraperitoneal injection. Tumor volume was measured every 3 days after starting treatment until day 24 in SUIT2 models, until day 28 in HuPT4 models, and until day 24 in PATC153 models. Data represent mean ± SD (n=5). *, P <0.05; NS: not significant. D. Immunohistochemistry of KI-67, Cleaved CASPASE 3, and VIMENTIN in each group. Scale bars, 200 um. E. Staining`s quantification by measurement of NOVARED positive area/Nuclear area. Data represent mean ± SD (n=5). **, P <0.01; *, P <0.05.